HER2 PET/CT scan to predict treatment response in bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial uses a special PET/CT scan to see if your bladder cancer has HER2 proteins, which can help predict how well you will respond to a targeted antibody-drug conjugate treatment. It is for people with advanced bladder cancer who have already tried certain standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a good performance status (ECOG 0 or 1).
- Your bladder cancer has spread or cannot be removed by surgery.
- Your tumor is HER2 positive or suspected to be HER2 positive.
- You have already been treated with trastuzumab and a taxane chemotherapy, either for advanced disease or within 6 months after initial treatment.
- Your heart, bone marrow, kidneys, liver, and blood clotting function are working well enough.
- You are about to receive an anti-HER2 antibody-drug conjugate (ADC) treatment, and your life expectancy is more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
This trial studies a special PET/CT scan tracer that is designed to bind to a protein (Nectin-4) found in some bladder cancers. It aims to help doctors see and stage tumors more clearly, which could improve diagnosis and treatment planning.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
This study is testing whether a special PET scan (HER2-PET) can help predict how well the drug T-DXd (also known as Enhertu) might work for your breast cancer. T-DXd is a targeted therapy that delivers chemotherapy directly to cancer cells with certain markers. The trial will check if the scan can identify which patients are more likely to benefit, which could help personalize treatment.
This study tests an imaging technique that uses a special tracer to attach to HER2 (a protein on some cancer cells) and make it visible on a PET/CT scan. The goal is to see if the tracer can help doctors understand where HER2 is in the body, which may guide future treatment options for advanced lung cancer.
Hear when a new HER2 Positive or Suspicious Positive Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.